Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTOR
2023-510262-27-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rivaroxaban in Behçet's disease (BD) and deep vein thrombosis (DVT) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Rate of success at 6 months. Planned start Nov 2024; status: authorised.
02
Drugs
rivaroxaban
03
Conditions
Behçet's disease (BD)deep vein thrombosis (DVT)
Beyond the preview
Go deeper on 2023-510262-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510262-27-00.